iconstar paper   HIV Articles  
Back grey arrow rt.gif
ECLAIR Study of Cabotegravir (CAB) LA Injections:
Characterization of Safety and PK During the "PK Tail" Phase
  Oct 17-21 HIVR4P - HIV Research for Prevention: AIDS Vaccine, Microbicide, and ARV-Based Prevention Science, Chicago, Ill.
Reported by Jules Levin
Susan L. Ford,1 Britt S. Stancil,1 Martin Markowitz,2 Ian Frank,3 Robert M. Grant,4,5 Kenneth H. Mayer,6,7,8 Richard Elion,9 Deborah Goldstein,9 Chester Fisher,10 Magdalena E. Sobieszczyk,11 Joel E. Gallant,12 Hong Van Tieu,13 Winkler Weinberg,14 David A. Margolis,15 Krischan J. Hudson,15 Parul Patel,15 Alex R. Rinehart,15 Kimberly Y. Smith,15 William R. Spreen15
1PAREXEL International, Research Triangle Park, NC, USA; 2The Aaron Diamond AIDS Research Center, an affiliate of the Rockefeller University, New York, NY, USA; 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 4Institute of Virology and Immunology, Gladstone Institutes, San Francisco, CA, USA; 5Department of Medicine, University of California, San Francisco, CA, USA; 6The Fenway Institute, Fenway Health, Boston, MA, USA; 7Beth Israel Deaconess Medical Center, Boston, MA, USA; 8Harvard Medical School, Boston, MA, USA; 9Whitman Walker Health, Washington, DC, USA; 10Health Research of Hampton Roads, Newport News, VA, USA; 11Columbia University Medical Center, New York, NY, USA; 12Southwest CARE Center, Santa Fe, NM, USA; 13New York Blood Center, New York, NY, USA; 14Kaiser Permanente, Atlanta, GA, USA; 15ViiV Healthcare, Research Triangle Park, NC, USA






  iconpaperstack View Older Articles   Back to Top   www.natap.org